Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.15 (4.62%)
Spread: 0.10 (3.03%)
Open: 3.25
High: 3.40
Low: 3.40
Prev. Close: 3.40
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

Wed, 27th Mar 2024 11:02

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Norman Broadbent PLC, up 13% at 8.75 pence, 12-month range 4.50p-9.32p. The London-based recruitment firm swings to a pretax profit in 2023 of GBP309,000 from a loss of GBP338,000 in 2022. This tracks revenue rising 41% to GBP12.3 million from GBP8.7 million, partially offset by operating expenses rising 34%to GBP10.2 million from GBP7.6 million and cost of sales rising 21% to GBP1.7 million from GBP1.4 million. Chief Executive Officer Kevin Davidson comments: "We have taken the opportunity to invest further in the Company, hiring exceptional people and building our platform to take advantage of the market rebound when it comes. Our ambition remains steadfast and we will continue to pursue our aggressive growth strategy, whilst remaining profitable and cash positive, both organically and potentially through synergistic M&A opportunities...Supported by our considerable brand strength and market leading processes and technologies, we are well-positioned for continued success."

----------

Allergy Therapeutics PLC, up 11% at 3p, 12-month range 0.37p-3.20p. In the six months that ended December 31, the Sussex, England-based biotechnology company reports pretax loss widening to GBP14.9 million from GBP8.2 million a year earlier. Revenue falls 16% to GBP33.6 million from GBP39.9 million, while financial expenses soar to GBP3.2 million from GBP398,000. Chief Executive Officer Manuel Llobet comments: "2023 has been an important year, marked by a highly focused approach to our business priorities, and a steadfast commitment to our Grass and Peanut allergy research & development programmes. We have navigated the challenges of last year, resulting in more streamlined operations and improved cost-effectiveness. This progress starts to pave the way towards a return to growth." Allergy Therapeutics also notes that its lenders have agreed that a further GBP15 million may be drawn from the existing GBP40 million amended loan facility from the second quarter of calendar 2024, with the first GBP7.5 million having already been drawn down. It says this extends its cash runway into the first quarter of its financial 2025. The lenders are major shareholders SkyGem Acquisition, which is an affiliate ZQ Capital Management, alongside Southern Fox Investments.

----------

AIM - LOSERS

----------

Infrastructure India PLC, down 80% at 0.10p, 12-month range 0.10p-1.27p. In the six months that ended September 30, the infrastructure fund investing directly into assets in India reports pretax loss narrowing to GBP31.5 million from GBP62.2 million a year earlier, largely driven by foreign exchange loss narrowing to GBP3.7 million from GBP40.8 million. Shares restarted trading on Wednesday after publishing its annual results for the financial year ended March 31 on Tuesday. During this period, pretax loss widened to GBP59.2 million from GBP48.4 million a year earlier. The company says: "The group has prepared the interim results on a basis other than going concern due to the uncertainty in relation to the timing of potential transactions, ultimate receipt of sale proceeds and the specifics of any deferred consideration. This basis was considered the most appropriate method for the reporting period."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
25 Sep 2019 11:26

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Read more
27 Jun 2019 10:07

Allergy Therapeutics earnings set to top expectations

(Sharecast News) - Biotechnology group Allergy Therapeutics told investors on Thursday that 2019 full-year earnings looked set to come in ahead of market expectations.

Read more
19 Jun 2019 13:39

Allergy Therapeutics Hires Former Advanced Medical Solutions CFO

(Alliance News) - Allergy Therapeutics PLC on Wednesday said it has appointed Mary Tavener as a non-executive director with immediate effect.The biotechnology company said Tavener has in 19

Read more
20 May 2019 13:42

Allergy Therapeutics Vaccine Helps Dust Mite Allergy Symptoms In Study

LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said its Acarovac MPL vaccine improved dust mite allergy symptoms during a phase one study.The AM101 study, which was open-label

Read more
20 May 2019 11:00

Allergy Therapeutics flags positive outcomes from recent treatment trial

(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous 'Acarovac MPL' (monophosphoryl lipid A) in patients with house dust mite-induced allergic rhinoconjunctivitis on Monday.

Read more
25 Apr 2019 10:01

Allergy Therapeutics eyes 2020 start for hay fever inoculation trials

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics will kick off phase III trials of its short-course inoculation for grass pollen-induced hay fever in the second half of 2020 following a successful round of meetings with German and American regulatory bodies.

Read more
18 Mar 2019 10:44

WINNERS & LOSERS SUMMARY: Footasylum Rises On "Generous" JD Offer

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - Tinto, up 2.3%, Group, up in

Read more
18 Mar 2019 10:06

Allergy Therapeutics Surprised As Vaccine Trial Fails Primary Endpoint

LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said a phase three trial of its birch pollen allergy vaccine did not meet its primary endpoint.Shares in Allergy Therapeutics 43%

Read more
18 Mar 2019 08:51

Allergy Therapeutics shares plunge after disappointing clinical trial

(Sharecast News) - Shares in biotechnology company Allergy Therapeutics were plunging on Monday morning, after it announced disappointing top-line results from the phase 3 clinical trial 'B301' of its new adjuvanted birch allergoid product.

Read more
6 Mar 2019 11:13

Allergy Therapeutics Interim Profit Rises 67% On Higher Revenue

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday reported significantly higher profit for the first six months of its financial year as revenue rose and research costs were the to of

Read more
6 Mar 2019 10:19

Allergy Therapeutics profits rise as it spends less on R&D

(Sharecast News) - Specialty pharmaceutical group Allergy Therapeutics announced its unaudited interim results for the six months ended 31 December on Wednesday, reporting a 10.6% improvement in revenue on both a reported and constant currency basis, to £46.7m.

Read more
16 Jan 2019 12:26

Allergy Therapeutics First Half Meets Forecasts On European Growth

LONDON (Alliance News) - Allergy immunology vaccines developer Allergy Therapeutics PLC said Wednesday trading in the first half was in line with expectations.Allergy Therapeutics expects -

Read more
16 Jan 2019 08:51

Allergy Therapeutics sees good first-half progress

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market for the six months ended 31 December on Wednesday, reporting that it was trading in line with board expectations.

Read more
27 Nov 2018 13:12

Allergy Therapeutics Continues To Perform Well, Revenue Up "Strongly"

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday it has continued to perform well, with revenue up "strongly" from the prior year and sales in line with market financial to

Read more
27 Nov 2018 10:05

Allergy Therapeutics boosted by strong German performance

(Sharecast News) - Biotechnology company Allergy Therapeutics has seen revenues increase throughout the first half of its trading year thanks to an improved market share for its allergy vaccines on the continent.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.